Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance Life Sciences Services revenue grew 18% year-over-year in FY 2

Fourth Quarter and Full-Year 2025 Financial Results

Tennessee, March 3, 2026, - Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading

global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results

for its fourth quarter (Q4) and year ended (FY) December 31, 2025.

Shelton, CEO of Cryoport, commented, "2025 was a year of strong progress for Cryoport. We delivered full-year revenue of $176.2

million, exceeding the high end of our previous guidance and reflecting continued momentum across our core markets. We achieved double-digit

revenue growth driven by expanding cell and gene therapy ("CGT") activity, with revenue from the support of commercial CGTs

increasing 29% year-over-year to a record $33.4 million for FY 2025. Revenue from the support of clinical trials also remained solid,

growing 14% to $47.1 million for FY 2025. At year-end, we supported a record 760 global clinical trials, representing approximately 70%

of CGT trials. We believe our leadership position across both clinical and commercial programs, and the breadth of the development pipeline

we support, provide a substantial foundation for sustained long-term growth.

continued to execute on our strategy of expanding our revenue streams and capturing more revenue per client as our Life Sciences Services

revenue increased 18% year-over-year for FY 2025, including 22% growth in BioStorage/BioServices revenue. This performance reflects the

expanding scale of the clinical and commercial programs we support and the increasing value customers place on our differentiated high-end

supply chain solutions. While our primary focus remains on accelerating revenue growth and strengthening our market position, we continue

to enhance operational discipline across the organization as we advance on our pathway to profitability. In 2025, our cost reduction

initiatives contributed to our consolidated gross margin of 47% and a $12 million year-over-year improvement in adjusted EBITDA from

continuing operations.

macro challenges, our Life Sciences Products segment grew 7% year-over-year and

continues to support our Services businesses. MVE Biological Solutions' (MVE) focus on innovation and execution continues

to further enhance its position as the global leader in the production of high- quality cryogenic systems. Recently MVE introduced integrated

Condition Monitoring Solutions for its dry vapor shippers and also launched the Fusion 800 Series, a revolutionary self-sustaining

cryogenic freezer that can fit through a single door, which opens up substantial market opportunities.

also increased our investments into Cryoport Systems to support the traction that we are seeing across our broad portfolio of CGT clients.

These targeted investments include the launch of our Global Supply Chain Center in Paris, France, the expansion of our Belgian operations

to accommodate a key commercial client, and the facility buildout to consolidate three existing facilities in Irvine, California into

one expansive Global Supply Chain Center in Santa Ana, California.

in 2025 we formed a strategic partnership with DHL Group, which included DHL's acquisition of CRYOPDP, providing a substantial capital

infusion. Over time, we believe this relationship will enhance our positioning in the EMEA and APAC regions and strengthen our competitive

industry profile. As part of our continuing strategic initiative to embed our market-leading solutions into the CGT ecosystem and improve

our growth trajectory, we expanded our global partnerships by entering into strategic collaborations with Cardinal Health and Parexel.

we enter 2026 and balance the global macro puts and takes, we believe that our full-year revenue guidance of $190 million to $194 million

is an appropriate starting point for the year," concluded Mr. Shelton.

In tabular form, Q4 2025

and FY 2025 revenue compared to Q4 2024 and FY 2024, respectively, were as follows:

Cryoport, Inc. and Subsidiaries

Solutions revenue increased 17% year-over-year for FY 2025, supported by increasing customer activity and program advancement within

the CGT market. BioStorage/BioServices revenue continued to experience strong year-over-year growth, increasing 22% for FY 2025, reflecting

our clients' interest in our expanded and integrated services offering that provides a seamless and secure handling of temperature-sensitive

materials through our global network.

from the support of commercial CGTs increased 29% year-over-year to $33.4 million and we supported twenty (20) commercial therapies as

of December 31, 2025.

year-end, Cryoport supported a total of 760 global clinical trials, a net increase of 59 clinical trials over FY 2024, with 86 of these

clinical trials in Phase 3. The number of trials by phase and region are as follows:

Cryoport Supported Clinical Trials by Phase

Cryoport Supported Clinical Trials by Region

2025, five Biologics License Applications (BLA) / Marketing Authorization Applications (MAA) filings occurred. Post quarter-end, two

additional BLA filings have occurred. During the fourth quarter, Cryoport's

customer, Fondazione Telethon received FDA approval for their gene therapy Waskyra for the treatment of Wiskott-Aldrich Syndrome (WAS).

During the fourth quarter, Bristol Myers Squibb received supplemental approval from the European Commission (EC) to expand the label

of Breyanzi as a third line treatment for relapsed or refractory follicular lymphoma. Lastly, in late December, Cryoport's

customer Inovio Pharmaceuticals' BLA filing for INO-3107 was accepted by the FDA as a potential treatment for adults with Recurrent

Respiratory Papillomatosis (RRP). For 2026, we anticipate 13 BLA/MAA application filings (including the two already filed), nine new

therapy approvals and an additional two approvals for label/geographic expansions. In the near term, Cryoport has three clients that

are anticipating new therapy approval decisions in March and April 2026.

Life Sciences Services

2025, the Company completed its previously announced divestiture of its specialty courier CRYOPDP business to DHL Supply Chain International

Holding B.V. ("DHL") as a part of a strategic partnership with DHL. The divestiture and strategic partnership are expected

to enhance the Company's ability to develop its business, particularly in the EMEA and APAC regions, and to provide differentiated

and high-value services aligned with Cryoport's long-term growth strategy. The results of CRYOPDP, a former business within Cryoport's

Life Sciences Services segment, are presented as discontinued operations for all periods presented within the Condensed Consolidated

Statements of Operations and Condensed Consolidated Balance Sheets included in this press release and are also not included in the non-GAAP

financial measures presented herein.

from Continuing Operations

Income (Loss) - including Discontinued Operations

EBITDA from Continuing Operations

Cash equivalents, and Short-Term Investments

for Full-Year Fiscal 2026

All reconciliations of GAAP to adjusted (non-GAAP) figures above are detailed in the reconciliation tables included later in the press

information on Cryoport's financial results is included in the attached condensed consolidated balance sheets and statements of

operations, and additional explanations of Cryoport's financial performance are provided in the Company's Annual Report on

Form 10-K for the year ended December 31, 2025, which is expected to be filed with the SEC on March 6, 2026. Additionally,

the full report will be available in the SEC Filings section of the Investor Relations section of Cryoport's website at www.cryoportinc.com.

Conference Call Information

INFORMATION: In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2025 in Review",

providing a review of Cryoport's business update, will be issued at 4:05 p.m. ET on Tuesday, March 3, 2026. The document

is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.

management will host a conference call at 5:00 p.m. ET on March 3, 2026. The conference call will be in the format of a questions

and answers session and will address any queries investors have regarding the Company's reported results. A slide deck will accompany

questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor

Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and

answers click here. A dial-in replay of the call will also be available to those interested, until March 10, 2026. To access

the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1189463#.

(Nasdaq: CYRX is a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with an

emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations

(CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability

across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal

Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices,

cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands

of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine ."

in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.

more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport

on X, formerly known as Twitter at https://x.com/cryoport for live updates.

in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations,

representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry,